肿瘤化疗辅助用药研究进展
induced and cisplatin-induced toxicities: Results of a randomized
19. Hortobagyi GN, Theriault RL, Porter L,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breasr cancer and lytic bone metastases. N Engl J Med, 1996,335:1785-1791.
20. Patterson AHG, Powel TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol,1993, 11: 59-65.
21. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol,1993,11:491-498.
22. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decrease the frequency of skeletal metastases in women with breast cancer. Bone, 1996,19: 663-667.
23. Van Holten-verzantrvoort AT, Hermas J, Beex LV, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patient? Eur J Cancer, 1996,32A:450-454.
24. Loyama, Uchida T, Takanuki F,et al. Pharmacokinetics of recombinant human interleukin-11（rhIL-11） in healthy male subjects. Br J Clin Pharmacol, 1997,43:571-578.
25. Tepler I, Elias L, Smith II JW,et al. A randomized placebo-controlled trial of recombinant human interliukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 1996,87（9）:3607-3614.
26. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol, 1997,15（11）:3368-3377.
本文链接地址：http://www.oyaya.net/fanwen/view/152771.html
control trail in patients with advanced ovarian cancer. J Clin Oncol, 1996,14:2101-2112.
19. Hortobagyi GN, Theriault RL, Porter L,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breasr cancer and lytic bone metastases. N Engl J Med, 1996,335:1785-1791.
20. Patterson AHG, Powel TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol,1993, 11: 59-65.
21. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol,1993,11:491-498.
22. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decrease the frequency of skeletal metastases in women with breast cancer. Bone, 1996,19: 663-667.
23. Van Holten-verzantrvoort AT, Hermas J, Beex LV, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patient? Eur J Cancer, 1996,32A:450-454.
24. Loyama, Uchida T, Takanuki F,et al. Pharmacokinetics of recombinant human interleukin-11（rhIL-11） in healthy male subjects. Br J Clin Pharmacol, 1997,43:571-578.
25. Tepler I, Elias L, Smith II JW,et al. A randomized placebo-controlled trial of recombinant human interliukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 1996,87（9）:3607-3614.
26. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol, 1997,15（11）:3368-3377.
《肿瘤化疗辅助用药研究进展(第9页)》
★读了本文的人也读了：